Hanall Biopharma Loses ICC Arbitration Over Batoclimab License Termination with Harbor BioMed, Agreement Remains Valid

The ICC arbitration tribunal ruled that Hanall Biopharma's termination notice for the HL161 batoclimab license agreement with Harbor BioMed was invalid, keeping the agreement in effect.
The ruling does not affect the ongoing gMG approval and commercialization process of batoclimab in China.
Although Hanall Biopharma failed to terminate the license, it can continue its partnership with Harbor BioMed to access the Chinese market.
[AI Summary]The ICC arbitration loss invalidates Hanall Biopharma's attempt to terminate the license, realizing legal risk. However, since the existing agreement continues, the Chinese business for batoclimab proceeds without disruption, limiting near-term negative share price impact.